WO2011079154A1 - Compositions et méthodes de traitement du vitiligo - Google Patents

Compositions et méthodes de traitement du vitiligo Download PDF

Info

Publication number
WO2011079154A1
WO2011079154A1 PCT/US2010/061661 US2010061661W WO2011079154A1 WO 2011079154 A1 WO2011079154 A1 WO 2011079154A1 US 2010061661 W US2010061661 W US 2010061661W WO 2011079154 A1 WO2011079154 A1 WO 2011079154A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
rapamycin
effective amount
cosmeceutically
Prior art date
Application number
PCT/US2010/061661
Other languages
English (en)
Inventor
Sarah Bacus
Original Assignee
Sarah Bacus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarah Bacus filed Critical Sarah Bacus
Priority to CA2822746A priority Critical patent/CA2822746A1/fr
Priority to EP10840093.8A priority patent/EP2515652A4/fr
Publication of WO2011079154A1 publication Critical patent/WO2011079154A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)

Definitions

  • the present invention relates to a novel skin composition that stops progression of vitiligo.
  • the invention further relates to a composition containing a compound functioning to inhibit T-cell killing in the melanocytes. More specifically, the invention relates to a composition containing rapamycin as an active ingredient.
  • the invention can contain fibroblast growth factor as an active ingredient.
  • the invention further relates to a composition for promoting the formation of collagen in the skin, wherein the composition comprises the aforementioned compound or compounds.
  • the invention also relates to a method of treating related skin signs of aging (hollowing or sagging of skin) through use of the composition.
  • the aging process has multiple effects on the overall thickness and elasticity of the cells which comprise the skin.
  • the amount of collagen produced is decreased and the type of collagen changes.
  • the elastin in the skin decreases, the melanin granules collect into areas of dark-colored blemishes, the cells of the skin become older and the layers of expired cells increases.
  • retin-A is used to increase collagen production, decrease elastin loss, decrease production of metalloproteases (which may cause oxidative damage to the skin), disperse melanin granules and exfoliate the layers of dead skin cells from the skin.
  • retin-A has some undesirable side effects and requires monitoring of sun exposure while treating skin.
  • treatments for aging skin such as hydroquinone (bleaches skin and slows melanin production), alpha hydroxy acid (acts similar to retin-A), anti-oxidants (e.g. Cellex-C, Prevage or Revale).
  • hydroquinone bleaches skin and slows melanin production
  • alpha hydroxy acid acts similar to retin-A
  • anti-oxidants e.g. Cellex-C, Prevage or Revale
  • Vitiligo is an autoimmune disease presenting with progressive loss of skin pigmentation.
  • Vitiligo is a cutaneous disease in which the melanocytes are destroyed in discrete patches, resulting in lightened areas of variable size and location distributed throughout the skin of the body.
  • Melanocytes are cells located in the stratum basale (bottom layer) of the skin's epidermis. They are also located in the eye, ear, meninges, bones and heart. Melanocytes produce a pigment called melanin, a derivative of the amino acid tyrosine, through the process of melanogenesis. Variations in the activity of melanocytes and the production of melanin is a primary determinant of human skin color.
  • the condition of vitiligo can also affect eye pigmentation and ear function, as melanin is expressed in both the ear and the uveal tract of the eye.
  • the lightened lesions of the skin are immunocompromised and generally have greater susceptibility to the damaging effects of the sun, premature aging and possible cancer of the skin.
  • the disease strikes about 1% of the world population, generally during teenage years.
  • the progressive loss of melanocytes from depigmenting vitiligo skin is accompanied by cellular infiltrates containing T lymphocytes. Infiltrating cytotoxic T cells with high affinity T cell receptors have likely escaped clonal deletion in the thymus, allowing such T cells to enter the circulation.
  • T cells home to the skin where they express type 1 -cytokine profiles and mediate melanocyte apoptosis via the granzyme/perforin pathway.
  • This condition affects the skin and is readily visible to the public eye, there are many psychological and social problems that can result.
  • treatments that can be used to minimize the visible consequences of a condition such as vitiligo, as well as other conditions which manifest themselves as discolorations of the skin (aging spots, liver spots, etc.).
  • compositions are disclosed for cosmeceuticals that aid in the retardation of the progression of vitiligo.
  • Methods for preparing cosmeceutical compositions for treating vitiligo are also disclosed. More specifically, the methods herein disclose the use of rapamycin for preventing the progression of vitiligo and the use of rapamycin and fibroblast growth factor for promoting collagen formation.
  • methods for preparing cosmeceutical compositions resulting in a promotion of collagen are also disclosed. More specifically, the methods herein disclose the use of rapamycin and fibroblast growth factor for promoting collagen formation.
  • the composition contains rapamycin in a cosmeceutically acceptable medium/vehicle that functions to reduce T-cell degradation of melanocytes and lessen the visual signs of vitiligo.
  • the composition contains additional ingredients, such as fibroblast growth factor to aid in collagen formation.
  • the composition contains vitamin E.
  • the composition contains tromethamine, glutathione peroxidase, and catalase.
  • the invention is adminstered topically.
  • the compositions is formulated as a leave-on product.
  • the composition contains about 0.001 to 0.5% by weight rapamycin.
  • the composition contains about 0.1 to 0.2% by weight rapamycin
  • the composition contains about 0.15% by weight rapamycin.
  • composition is used in a method of treating vitiligo involving topical administration of one of the rapamycin compositions disclosed.
  • the composition is used in a method of promoting collagen production involving topical administration of one of the rapamycin compositions disclosed
  • Another embodiment is a method of inhibiting T cells in melanocytes by administering an about 0. luM to 100 uM of rapamycin composition to the cells.
  • FIG. 1 Western blot of protein expression in Human Hepatocarcinoma, HH, (T- cell lymphoma) cells treated with increasing doses of rapamycin (0.1 - 100 uM).
  • the present invention is based on the discovery that drugs, such as rapamycin, actively inhibit T-cells and inhibit the process of T-cell maturation in the melanocytes. It has been further discovered that the use of rapamycin in cosmeceutical medium is an effective topical treatment for vitiligo. The response of vitiligo skin cells to treatment with rapamycin over a course of treatment (twice a day application of 2.5 uM cosmeceutical rapamycin composition) has shown response via reduction of the discoloration and reduction in the progression of the disease. In another aspect of the present invention, the use of rapamycin and fibroblast growth factor (FGF) promotes the production of collagen and reduces the visible effects of aging.
  • drugs such as rapamycin
  • FGF fibroblast growth factor
  • Rapamycin also called sirolimus
  • IL-2 interleukin-2
  • Rapamycin binds to the cytosolic protein F -binding protein 12 (FKBP12) and inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding the mTOR Complex 1 (mTORCl).
  • the treatment of vitiligo and the production of collagen with a rapamycin composition, an FGF composition or a rapamycin and FGF composition of the present invention has many desired effects in management of skin and skin disorders, including anti-ageing, anti- wrinkle and/or an anti-cellulite effects, minimizing the appearance of wrinkles, blemishes, skin lines, oily skin, acne, dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, age spots, dark circles around eyes, skin pigmentation, topical inflammation, liver spots, pigmented spots, wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, disturbed keratinization, dandruff, bacterial infection, fungal infection, wound healing, body odor, and skin changes associated with aging
  • composition according to the invention also comprises a dermatologically/cosmetically acceptable vehicle to act as a diluent, dispersant or carrier for the rapamycin.
  • vehicle can comprise materials commonly employed in skin care products such as water, liquid or solid emollients, silicone oils, emulsifiers, solvents, humectants, thickeners, powders, propellants and the like.
  • agents which can be employed in the present application as the dermatologically acceptable vehicle include fibroblast growth factor (FGF), tromethamine, glutathione peroxides, catalase, sphingoid and phospholipid derivatives, antioxidants and vitamins, antiinflammatories, botanical agents, moisturizing agents, skin whitening agents, peptides, caffeine and sunscreens and UV absorbers.
  • FGF fibroblast growth factor
  • tromethamine glutathione peroxides
  • catalase catalase
  • sphingoid and phospholipid derivatives antioxidants and vitamins
  • antiinflammatories botanical agents
  • moisturizing agents moisturizing agents
  • skin whitening agents peptides
  • peptides peptides
  • sunscreens and UV absorbers UV absorbers
  • vehicle ingredients include water, glycerin, hydrogenated polyisobutene, cetearyl alcohol, ceteareth-20, macadamia integrifolia seed oil (macademia nut oil), dimethicone, tocopheryl acetate, stearoxytrimethylsilane, stearyl alcohol, panthenol, farnesol, benzyl alcohol, phenoxyethanol, acrylates/C 10-30 alkyl acrylate crosspolymer, sodium hydroxide, citric acid for lotions or water, petrolatum, glyceryl polymethacrylate, dicaprylyl ether, glycerin, dimethicone, glyceryl stearate, cetyl alcohol, prunus amygdalus dulcis (sweet almond) oil, PEG-30 glyceryl stearate, tocopheryl acetate, benzyl alcohol, phenoxyethanol, sodium hydroxide, acrylates/C 10-30 alkyl
  • a preferred vehicle is Cetaphil®.
  • agents that can be added to the vehicle include: sphingoid and phospholipid derivatives (e.g. ceramides, phytosphingosine, sphingosine, pseudoceramides, phospholipids, lysophospholipids); antioxidants and vitamins (e.g. tocopherol and derivatives, ascorbic acid and derivatives, niacinamide and derivatives, vitamin complexes, alpha-lipoic acid, retinol and derivatives, panthenol); antiinflammatories (e.g.
  • the cosmeceutically effective amount of rapamycin that is used in the cosmeceutically acceptable composition has a concentration of about 0.5% to 0.00001% rapamycin preferably from about 0.5% to 0.1%.
  • the cosmeceutically effective amount of rapamycin is partially dependent on the cells or the individual being treated and higher concentrations may be necessary to achieve desired results, in addition higher concentrations may result in increased side effects.
  • the Formulation Table shows exemplary calculations for producing products of 0.01% and 0.005% rapamycin, similar calculations can be used to produce a cosmeceutically acceptable composition at the desired concentration.
  • ingredients that may be used in any combination in the composition with 10 gms of vehicle are indicated: addition of about 15 mgs of rapamycin is preferred (about 0.15% by weight), addition of about 0.5 ugm to about 1.5 ugm of fibroblast growth factor is preferred (about 0.00005% to 0.00015% by weight), addition of about 0.5 gms of tromethamine is preferred (about 0.5% by weight), addition of about 30 mgs of glutathione peroxides is preferred (about 0.3% by weight), addition of about 30 mgs of catalase is preferred (about 0.3% by weight), and addition of about 500 mgs of vitamin E is preferred (about 0.5% by weight).
  • the dermatologically acceptable vehicle will usually form from about 80% to about 99.999%, preferably from about 95% to about 99.985% and most preferably about 99.985% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
  • the rapamycin is maintained at a concentration of about 0.15% by weight in a cosmeceutically acceptable medium.
  • the fibroblast growth factor is maintained at a therapeutically effective concentration of about 0.000015% to about 0.00005% in a cosmeceutically acceptable medium.
  • the rapamycin and FGF together comprise about 0.15% by weight in a cosmeceutically acceptable medium.
  • the skin care formulation can be an aqueous solution, a water-in-oil (w/o) emulsion, an oil-in-water (o/w) emulsion, a dispersion of lipids, an aqueous, water-alcohol, oil or oil-alcohol gel, a solid stick, a wet-wipe or an aerosol.
  • a dermatologically acceptable vehicle itself is an (w/o) or (o/w) emulsion, it can contain 5 to 50% of an oilphase and 47 to 94.95% water, with respect to the weight of the whole formulation.
  • compositions Preparation, Form, Use and Packaging
  • the active components are generally incorporated in a dermatologically acceptable carrier in conventional manner.
  • the active components can suitably be dissolved or dispersed in a portion of the water or another solvent or liquid to be incorporated in the composition.
  • the preferred compositions are oil-in-water or water-in-oil emulsions.
  • the composition may be in the form of conventional skin-care products such as a cream, gel or lotion or the like.
  • the composition can also be in the form of a so-called "rinse-off 1 product, e.g., a bath or shower gel, possibly containing a delivery system for the actives to promote adherence to the skin during rinsing.
  • the product is a "leave-on” product; a product to be applied to the skin without a deliberate rinsing step soon after its application to the skin.
  • composition may be packaged in any suitable manner such as in ajar, a bottle, tube, roll-ball, or the like, in the conventional manner.
  • the active ingredients described in the present invention may be applied one or more times daily to the portion of skin requiring treatment.
  • the improvement in skin appearance will usually become visible after two weeks of treatment, depending on the status of the initial skin condition, the concentration of the active components used in the composition, the volume of composition used and the frequency of application.
  • a small quantity, about 0.25 ml, of the composition is applied to the skin from a suitable container or applicator and spread over and/or rubbed into the skin using the hands or fingers or a suitable device.
  • the composition is formulated as a "leave-on" product and does not require any gloves or special applicators for effective use. Once applied to the skin in the affected area, the composition will begin to elicit the desired effects for treating vitiligo and promoting collagen production.
  • Fig. 1 Human Hepatocarcinoma, HH, cells were treated with increasing doses of rapamycin (0.1 - 100 u ) and the protein expression profile was analyzed by Western blot.
  • the rapamycin treatment resulted in increased expression of pAcc (phosphorylated acetyl-CoA carboxylase), slightly increased expression of peEF2 (phosphorylated eukaryotic elongation factor 2) and decreased expression of pS6 (phosphorylated ribosomal protein S6).
  • pAcc phosphorylated acetyl-CoA carboxylase
  • peEF2 phosphorylated eukaryotic elongation factor 2
  • pS6 phosphorylated ribosomal protein S6
  • Vitilogstop is not a cure, but provides a noticeable diminishment of discoloration and enlargement of vitiligo spots usually after three months. Combined with other active ingredients, stimulation of new melanin occurs over time. Apply twice a day on affected sites. The cream may oxidize and darken with time but will remain effective throughout use.
  • a 0.4 mg/ul Rapamycin composition is made in DMSO as a stock solution, from which an aliquot of 187.5 uls of the stock solution is added to 200 gms of lotion or cosmeceutically acceptable medium and mixed thoroughly.
  • An FGF composition is made following a similar protocol for a cosmeceutically acceptable medium and mixed thoroughly. Additional concentrations can be made from a concentrated stock solution by methods known to one of ordinary skill in the art.
  • the cosmeceutical formulation (lotion) can be stored at ambient temperature for topical use on those areas of the skin wherein additional lipid production is desired.

Abstract

La présente invention concerne des compositions et méthodes pour traiter le vitiligo et favoriser la formation de collagène.
PCT/US2010/061661 2009-12-21 2010-12-21 Compositions et méthodes de traitement du vitiligo WO2011079154A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2822746A CA2822746A1 (fr) 2009-12-21 2010-12-21 Compositions et methodes de traitement du vitiligo
EP10840093.8A EP2515652A4 (fr) 2009-12-21 2010-12-21 Compositions et méthodes de traitement du vitiligo

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28868809P 2009-12-21 2009-12-21
US61/288,688 2009-12-21
US31567210P 2010-03-19 2010-03-19
US61/315,672 2010-03-19

Publications (1)

Publication Number Publication Date
WO2011079154A1 true WO2011079154A1 (fr) 2011-06-30

Family

ID=44196131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/061661 WO2011079154A1 (fr) 2009-12-21 2010-12-21 Compositions et méthodes de traitement du vitiligo

Country Status (3)

Country Link
EP (1) EP2515652A4 (fr)
CA (1) CA2822746A1 (fr)
WO (1) WO2011079154A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
EP2671583A1 (fr) * 2011-01-31 2013-12-11 Osaka University Médicament à usage externe pour traiter un trouble cutané et procédé pour produire celui-ci
CN104324367A (zh) * 2014-10-20 2015-02-04 广西壮族自治区花红药业股份有限公司 鱼鳞提取物在制备治疗和/或预防白癜风药物方面的新用途
EP3352755A4 (fr) * 2015-09-24 2019-04-03 Drexel University Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10493020B2 (en) 2016-04-14 2019-12-03 The Procter & Gamble Company Method of improving the appearance of periorbital dyschromia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6936426B2 (en) * 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
US20110130705A1 (en) * 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2515652A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2671583A1 (fr) * 2011-01-31 2013-12-11 Osaka University Médicament à usage externe pour traiter un trouble cutané et procédé pour produire celui-ci
EP2671583A4 (fr) * 2011-01-31 2014-09-03 Univ Osaka Médicament à usage externe pour traiter un trouble cutané et procédé pour produire celui-ci
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
CN104324367A (zh) * 2014-10-20 2015-02-04 广西壮族自治区花红药业股份有限公司 鱼鳞提取物在制备治疗和/或预防白癜风药物方面的新用途
EP3352755A4 (fr) * 2015-09-24 2019-04-03 Drexel University Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
US10695326B2 (en) 2015-09-24 2020-06-30 Drexel University Compositions and methods for treating or preventing dermal disorders
AU2016325446B2 (en) * 2015-09-24 2021-05-13 Drexel University Novel compositions and methods for treating or preventing dermal disorders
US11179374B2 (en) 2015-09-24 2021-11-23 Drexel University Compositions and methods for treating or preventing dermal disorders

Also Published As

Publication number Publication date
CA2822746A1 (fr) 2011-06-30
EP2515652A1 (fr) 2012-10-31
EP2515652A4 (fr) 2014-11-26

Similar Documents

Publication Publication Date Title
US8946256B2 (en) Compositions and methods for treatment of vitiligo
JP4234137B2 (ja) ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整
US6753000B2 (en) Hydroxystilbene/ascorbic acid compositions for treating skin afflictions
US9387160B2 (en) Composition and method of treating skin conditions
JP2002542177A (ja) 哺乳類のケラチン性組織の状態を調節する方法
US20070042026A1 (en) Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
US6267971B1 (en) Use of cinnamic acid or of its derivatives in a cosmetic firming composition
CA2635784C (fr) Heteromeres d'arginine pour administration locale
JP2003535115A (ja) 化粧品及び外皮用剤におけるリポ酸の（ｒ）−鏡像異性体の使用
JP2008156349A (ja) 加齢の徴候を処置するためのプロビタミンａ活性を有する少なくとも１種のカロチノイドとプロビタミンａ活性を有さない少なくとも１種のカロチノイドの組合せ物の使用
US20110150798A1 (en) Compositions and methods for increasing cellular far and bleaching skin
US20160175223A1 (en) Anti-aging compositions comprising bile acid-fatty acid conjugates
WO2011079154A1 (fr) Compositions et méthodes de traitement du vitiligo
US20110250157A1 (en) Skin Hyperpigmentation Acyl Glutathione Treatments
US20030068349A1 (en) Use of 5'-deoxy-5'-methylthioadenosine in skin cosmetic compositions
US20150202187A1 (en) Compositions and methods for treatment of vitiligo
JP2004512295A (ja) 皮膚加齢の徴候を処置するための少なくとも１種のカロチノイドと少なくとも１種のイソフラボノイドの組合せ物の使用
CA2411058C (fr) Traitement cutane a l'aide d'un nouveau retinoide
KR20170066419A (ko) 10-하이드록시스테아르산을 포함하는 화장품 조성물의 용도
EP2133066A1 (fr) Composition cosmétique et dermatologique contenant un mélange de dérivés de rétinol et des tocotriénols.
JP2002544218A (ja) 哺乳動物のケラチン組織状態を調整する方法
KR101582652B1 (ko) 주름개선용 화장료 조성물
EP1310241B1 (fr) Traitement cutané utilisant un rétinoide
WO2011084824A1 (fr) Compositions et méthodes pour l'augmentation de la graisse cellulaire et le blanchiment de la peau
KR20170033145A (ko) 아비에타트리엔을 유효성분으로 포함하는 피부 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10840093

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010840093

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010840093

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2822746

Country of ref document: CA